- Home
- Automated
- List of product information
- COMBIVENT UNIT DOSE VIAL FOR INHALATION [SIN09558P]
COMBIVENT UNIT DOSE VIAL FOR INHALATION [SIN09558P]
Active ingredients: COMBIVENT UNIT DOSE VIAL FOR INHALATION
Last updated 26 October 2025
On this page
Product Info
COMBIVENT UNIT DOSE VIAL FOR INHALATION
[SIN09558P]
Product information
Active Ingredient and Strength | IPRATROPIUM BROMIDE MONOHYDRATE 0.52 MG/2.5 ML EQV. TO IPRATROPIUM BROMIDE ANHYDROUS - 0.5 MG/2.5 ML |
Dosage Form | SOLUTION |
Manufacturer and Country | LABORATOIRE UNITHER - FRANCE |
Registration Number | SIN09558P |
Licence Holder | BOEHRINGER INGELHEIM SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | R03AK04 |
4.1 Therapeutic indications
COMBIVENT® nebuliser solution in unit dose vials are indicated for the management of reversible bronchospasm associated with obstructive airway diseases in patients who require more than a single bronchodilator.
4.2 Posology and method of administration
SPECIAL POPULATIONS
Patients with hepatic or renal impairment
COMBIVENT® has not been studied in patients with hepatic or renal insufficiency. It should be used with caution in those patient populations.
Paediatric population
Because of insufficient information in children COMBIVENT® is not indicated for paediatric patients.
Patients should be advised to consult a physician or the nearest hospital immediately in the case of acute or rapidly worsening dyspnoea if additional inhalations of COMBIVENT® do not produce an adequate improvement.
If higher than recommended doses of COMBIVENT® are required to control symptoms, the patient’s therapy plan should be reviewed.
In asthma, concomitant anti-inflammatory therapy should be considered.
The following doses of COMBIVENT® are recommended for adults (including elderly patients):
COMBIVENT® nebuliser solution in unit dose vials (UDVs)
COMBIVENT® nebuliser solution in unit dose vials may be administered from a suitable nebuliser or an intermittent positive pressure ventilator.
Treatment should be initiated and administered under medical supervision, e.g. in the hospital setting. Home based treatment can be recommended in exceptional cases (severe symptoms or experienced patients requiring higher doses) when a low dose rapid acting beta-agonist bronchodilator has been insufficient in providing relief after consultation with an experienced physician.
The treatment with the nebuliser solution in UDVs should always be started with the lowest recommended dose (1 UDV). In very severe cases two unit dose vials may be required for symptom relief. Administration should be stopped when sufficient symptom relief is achieved.
Treatment of acute attacks:
1 unit dose vial is sufficient for prompt symptom relief in many cases.
In severe cases if an attack has not been relieved by one unit dose vial, the administration of a second unit dose vial may be required. Patients should be advised to consult the physician or the nearest hospital immediately in these cases.
Maintenance treatment:
1 unit dose vial three or four times daily.
Instructions for use
The unit dose vials are intended only for inhalation with suitable nebulising devices and must not be taken orally or administered parenterally.
The content of the unit dose vials does not need to be diluted for nebulization.
Since the unit dose vials contain no preservative, it is important that the contents are used soon after opening and that a fresh vial is used for each administration to avoid microbial contamination. Partly used, opened or damaged unit dose vials should be discarded.
It is strongly recommended not to mix COMBIVENT® nebuliser solution with other drugs in the same nebuliser.
4.3 Contraindications
COMBIVENT® is contraindicated in patients with hypertrophic obstructive cardiomyopathy or tachyarrhythmia. COMBIVENT® is also contraindicated in patients with a history of hypersensitivity to atropine or its derivatives or to any other component of the product.